N4 Pharma (GB:N4P) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
N4 Pharma has filed a new patent for its innovative oral anti-inflammatory product targeting Irritable Bowel Disease (IBD) using its proprietary Nuvec® delivery system. The product aims to replace current treatments with significant side effects by utilizing nanoparticles to deliver RNA that inhibits inflammation and boosts natural defenses in the gut. This development highlights N4 Pharma’s commitment to advancing RNA therapeutics and attracting potential investors and collaborators.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.